Ibritumomab tiuxetan (Zevalin)

Page credits
Jump to navigation Jump to search
This page was last edited 23:32, 2 September 2023 by Jeremy Warner. Based on work by Jeremy L. Warner MD, MS, Peter Yang MD, HemOnc.org, Austin Fitts and Vivian.